Day

June 13, 2019

13
Jun
2019

Who Will Be the Next Celgene of Dealmaking?

Stars aligned beautifully, not long ago, for dealmaking at Celgene. The company, early this decade, was raking in the dough from the multiple myeloma drug Revlimid. Cash had to be spent somewhere. Celgene didn’t have much of its own R&D. Shareholders weren’t clamoring for their cut, via quarterly cash dividends. The stock soared, without any jet fueled-share buybacks. Letting cash...
Read More
13
Jun
2019

Predicting Who Will Benefit from Cancer Drugs: Liz O’Day on The Long Run

Today’s guest on The Long Run is Liz O’Day. Liz is the founder and CEO of Cambridge, Mass.-based Olaris Therapeutics. This is a scrappy little startup that’s studying metabolites that could provide clues for predicting which patients are most likely to respond to certain cancer drugs. Figuring out which patients are likely to respond is one of those perennial challenges...
Read More